Pranlukast attenuates ischemia-like injury in endothelial cells via inhibiting reactive oxygen species production and nuclear factor-κB activation

Journal of Cardiovascular Pharmacology

Volumn 53, Issue 1, 2009, Pages 77-85

  Fang, San Hua ^a   Yuan, Yu Mei ^a   Peng, Fang ^b   Li, Cheng Tan ^a,c   Zhang, Li Hui ^c   Lu, Yun Bi ^a   Zhang, Wei Ping ^a   Wei, Er Qing ^a,d  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

^d NONE   (China)

Author keywords

Endothelial cell; Nuclear factor B; Oxygen glucose deprivation; Pranlukast; Reactive oxygen species

Indexed keywords

GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR; MESSENGER RNA; NORPHENAZONE; OXYGEN; PEPTIDOLEUKOTRIENE RECEPTOR 1; PEPTIDOLEUKOTRIENE RECEPTOR 2; PRANLUKAST; PYRROLIDINE DITHIOCARBAMATE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ZILEUTON; ARACHIDONATE 5 LIPOXYGENASE; CHROMONE DERIVATIVE; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DAMAGE; CELL DEATH; CELL NUCLEUS; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; NECROSIS;

ARACHIDONATE 5-LIPOXYGENASE; CELL LINE; CELL NUCLEUS; CELL SURVIVAL; CHROMONES; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; ISCHEMIA; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE D4; LEUKOTRIENES; NECROSIS; NF-KAPPA B; OXYGEN; REACTIVE OXYGEN SPECIES;

EID: 67651087119     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318196736c     Document Type: Article

References (42)

1. Capra V, Thompson MD, Sala A, et al. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev. 2007;27:469-527. (Pubitemid 46984658)
2. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med. 2003;2:139-156.
3. Keam SJ, Lyseng-Williamson KA, Goa KL. Pranlukast: a reviewof its use in the management of asthma. Drugs. 2003;63:991-1019. (Pubitemid 36570535)
4. Fang SH, Wei EQ, Zhou Y, et al. Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience. 2006;140: 969-979. (Pubitemid 43767454)
5. Yu GL, Wei EQ, Wang ML, et al. Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice. Brain Res. 2005;1053:116-125.
6. Wang ML, Huang XJ, Fang SH, et al. Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression. Biochem Biophys Res Commun. 2006;350:399-404.
7. Zhang WP, Wei EQ, Mei RH, et al. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin. 2002;23:871-877.
8. Kim JH, Yu YS, Kim KW, et al. The role of clusterin in in vitro ischemia of human retinal endothelial cells. Curr Eye Res. 2007;32:693-698. (Pubitemid 47400687)
9. Xu J, He L, Ahmed SH, et al. Oxygen-glucose deprivation induces inducible nitric oxide synthase and nitrotyrosine expression in cerebral endothelial cells. Stroke. 2000;31:1744-1751. (Pubitemid 30437532)
10. Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets. 2007;11:123-132. (Pubitemid 46188809)
11. Mohan S, Koyoma K, Thangasamy A, et al. Low shear stress preferentially enhances IKK activity through selective sources of ROS for persistent activation of NF-kappaB in endothelial cells. Am J Physiol Cell Physiol. 2007;292:C362-C371. (Pubitemid 46115144)
12. Chandrasekar B, Colston JT, de la Rosa SD, et al. TNF-alpha and H2O2 induce IL-18 and IL-18R beta expression in cardiomyocytes via NF-kappa B activation. Biochem Biophys Res Commun. 2003;303:1152-1158.
13. Vanden Hoek TL, Li C, Shao Z, et al. Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion. J Mol Cell Cardiol. 1997;29:2571-2583. (Pubitemid 27404448)
14. Lin YH, Liu AH, Pan Y, et al. Reduction in the in vitro expression of brain-pancreas relative protein by oxygen and glucose-deprivation. Mol Cell Biochem. 2007;295:199-204. (Pubitemid 46158002)
15. Stephenson D, Yin T, Smalstig EB, et al. Transcription factor nuclear factor-kappa B is activated in neurons after focal cerebral ischemia. J Cereb Blood Flow Metab. 2000;20:592-603. (Pubitemid 30164903)
16. Nurmi A, Lindsberg PJ, Koistinaho M, et al. Nuclear factor-kappa B contributes to infarction after permanent focal ischemia. Stroke. 2004;35: 987-991. (Pubitemid 38419815)
17. Seegers H, Grillon E, Trioullier Y, et al. Nuclear factor-kappa B activation in permanent intraluminal focal cerebral ischemia in the rat. Neurosci Lett. 2000;288:241-245. (Pubitemid 30411924)
18. Ichiyama T, Hasegawa S, Umeda M, et al. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003;33:802-807. (Pubitemid 36760513)
19. Ishinaga H, Takeuchi K, Kishioka C, et al. Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology. 2005;73:89-96. (Pubitemid 40082319)
20. Higuchi Y, Otsu K, Nishida K, et al. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2002;34:233-240. (Pubitemid 35222832)
21. Dimayuga FO,Wang C, Clark JM, et al. SOD1 overexpression alters ROS production and reduces neurotoxic inflammatory signaling in microglial cells. J Neuroimmunol. 2007;182:89-99.
22. Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci U S A. 1983;80:3734-3737.
23. Bouis D, Hospers GA, Meijer C, et al. Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis. 2001;4:91-102. (Pubitemid 34032695)
24. Ahn K, Pan S, Beningo K, et al. A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 1995;56: 2331-2341.
25. Ge QF, Wei EQ, Zhang WP, et al. Activation of 5-lipoxygenase after oxygen-glucose deprivation is partly mediated via NMDA receptor in rat cortical neurons. J Neurochem. 2006;97:992-1004.
26. Ge QF, Hu X, Ma ZQ, et al. Baicalin attenuates oxygen-glucose deprivation-induced injury via inhibiting NMDA receptor-mediated 5-lipoxygenase activation in rat cortical neurons. Pharmacol Res. 2007; 55:148-157. (Pubitemid 46186042)
27. Gomes A, Fernandes E, Lima JL. Fluorescence probes used for detection of reactive oxygen species. J Biochem Biophys Methods. 2005;65:45-80. (Pubitemid 41827578)
28. Gauvreau GM, Plitt JR, Baatjes A, et al. Expression of functional cysteinyl leukotriene receptors by human basophils. J Allergy Clin Immunol. 2005;116:80-87. (Pubitemid 40909752)
29. Fordel E, Thijs L, Martinet W, et al. Anoxia or oxygen and glucose deprivation in SH-SY5Y cells: a step closer to the unraveling of neuroglobin and cytoglobin functions. Gene. 2007;398:114-122. (Pubitemid 47068903)
30. Zhang LH, Wei EQ. Neuroprotective effect of ONO-1078, a leukotriene receptor antagonist, on transient global cerebral ischemia in rats. Acta Pharmacol Sin. 2003;24:1241-1247.
31. Hu X, Ge QF, Zhang WP, et al. Effects of cysteinyl receptor agonist and antagonists on rat primary cortical neurons. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007;36:117-122.
32. Traystman RJ, Kirsch JR, Koehler RC. Oxygen radical mechanisms of brain injury following ischemia and reperfusion. J Appl Physiol. 1991;71: 1185-1195.
33. Shichinohe H, Kuroda S, Yasuda H, et al. Neuroprotective effects of the free radical scavenger edaravone (MCI-186) in mice permanent focal brain ischemia. Brain Res. 2004;1029:200-206. (Pubitemid 39470176)
34. Arii K, Kumon Y, Sugahara K, et al. Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B. Mol Immunol. 2008;45:463-469. (Pubitemid 47332633)
35. Kokura S, Yoshida N, Sakamoto N, et al. The radical scavenger edaravone enhances the anti-tumor effects of CPT-11 in murine colon cancer by increasing apoptosis via inhibition of NF-kappaB. Cancer Lett. 2005;229: 223-233. (Pubitemid 41429361)
36. Tomari S, Matsuse H, Machida I, et al. Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, attenuates allergen-specific tumour necrosis factor alpha production and nuclear factor kappa B nuclear translocation in peripheral blood monocytes from atopic asthmatics. Clin Exp Allergy. 2003;33:795-801. (Pubitemid 36760512)
37. Fukushima C, Matsuse H, Hishikawa Y, et al. Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol. 2005;136:165-172. (Pubitemid 40463242)
38. Obata T, Okada Y, Motoishi M, et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992;60:227-237.
39. Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999;56:657-663. (Pubitemid 29406893)
40. Marchese A, McHugh C, Kehler J, et al. Determination of pranlukast and its metabolites in human plasma by LC/MS/MS with PROSPEKT on-line solid-phase extraction. J Mass Spectrom. 1998;33:1071-1079. (Pubitemid 28521491)
41. Brocks DR, Upward J, Davy M, et al. Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers. Br J Clin Pharmacol. 1997;44: 289-291. (Pubitemid 27376258)
42. Okubo K, Baba K. A double-blind non-inferiority clinical study of montelukast, a cysteinyl leukotriene receptor 1 antagonist, compared with pranlukast in patients with seasonal allergic rhinitis. Allergol Int. 2008;57: 383-390.